Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Saadettin Kılıçkap, Mahmut Gümüş et al. · The Lancet · 2021

Cited by 787 works. doi:10.1016/s0140-6736(21)00228-2

Authors

References